Detalhe da pesquisa
1.
Morphological Evaluation and Immunohistochemical Analysis of the Reparative Potential of the Buccal Fat Pad.
Medicina (Kaunas);
60(4)2024 Mar 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38674213
2.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Blood;
138(21): 2042-2050, 2021 11 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34407543
3.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood;
138(21): 2031-2041, 2021 11 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34407542
4.
Xerostomia and hyposalivation in patients with obstructive sleep apnoea.
Clin Otolaryngol;
46(4): 782-787, 2021 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33548090
5.
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
Br J Haematol;
190(6): 869-876, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32227648
6.
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Am J Hematol;
94(11): 1236-1243, 2019 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31456269
7.
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Ann Intern Med;
168(7): 461-470, 2018 04 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29459949
8.
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.
Br J Haematol;
179(2): 219-228, 2017 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28699641
9.
Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia.
BMC Genet;
17 Suppl 1: 14, 2016 Jan 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26822197
10.
The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells.
Eur J Haematol;
97(3): 245-52, 2016 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26643284
11.
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Am J Hematol;
90(9): 755-68, 2015 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26040495
12.
Risks and challenges of CML management during pregnancy: Looking for a balanced decision.
Eur J Haematol;
102(4): 378-379, 2019 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30672625
13.
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Am J Hematol;
89(7): 732-42, 2014 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24711212
14.
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
Leukemia;
38(4): 788-795, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38388649
15.
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Blood;
118(17): 4567-76, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21865346
16.
Oral Galvanism Side Effects: Comparing Alloy Ions and Galvanic Current Effects on the Mucosa-like Model.
J Funct Biomater;
14(12)2023 Dec 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38132818
17.
The Impact of Commercially Available Dry Mouth Products on the Corrosion Resistance of Common Dental Alloys.
Materials (Basel);
16(11)2023 Jun 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37297329
18.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia;
37(3): 617-626, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36717654
19.
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease.
Clin Lymphoma Myeloma Leuk;
23(8): 589-598, 2023 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37236904
20.
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Cancer;
118(1): 118-26, 2012 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21732337